Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
Sponsor: Fazaia Ruth Pfau Medical College
Summary
To evaluate the efficacy of metformin as an adjunct therapy in improving depressive symptoms and metabolic markers in newly diagnosed obese depressed patients on standard antidepressant therapy. investigator will compare between Two groups 1\. metformin group 2 placebo group Primary outcome measure will be the improvement in depressive symptoms, indicating by a reduction in Hamilton Depression Rating Scale (HAM-D) scores. Secondary outcome measures will include the assessment of oxidative stress markers, specifically by measuring the increase in enzymatic activity of superoxide dismutase, catalase, and glutathione peroxidase Investigators hypothesize that the addition of metformin to standard antidepressant treatment will result in a significant reduction in symptoms of depression among newly diagnosed obese individuals.
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2025-10-01
Completion Date
2026-12
Last Updated
2025-09-19
Healthy Volunteers
No
Conditions
Interventions
Metformin Hydrochloride
Participants will be divided in 2 groups 1 group will receive metformin and 2nd group will receive placebo
Locations (2)
Fazaia Rurh Pfau Medical College
Karachi, Sindh, Pakistan
Fazaia Ruth Pfau Medical College
Karachi, Sindh, Pakistan